Recarbrio Drug Interactions: 7 Major, 219 Moderate
Recarbrio (Imipenem Anhydrous, Cilastatin, And Relebactam Anhydrous) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Recarbrio. Always confirm against the full prescribing information.
100 interactions
Acenocoumarol
The risk or severity of bleeding can be increased when Imipenem is combined with Acenocoumarol.
Level 2 evidence
Acetazolamide
The therapeutic efficacy of Acetazolamide can be decreased when used in combination with Imipenem.
Level 2 evidence
Acetylsalicylic acid
The excretion of Relebactam can be decreased when combined with Acetylsalicylic acid.
Level 2 evidence
Acyclovir
The excretion of Acyclovir can be decreased when combined with Cilastatin.
Level 2 evidence
Acyclovir
The excretion of Relebactam can be decreased when combined with Acyclovir.
Level 2 evidence
Allopurinol
The excretion of Allopurinol can be decreased when combined with Cilastatin.
Level 2 evidence
Amifampridine
The risk or severity of seizure can be increased when Imipenem is combined with Amifampridine.
Level 2 evidence
Amobarbital
The therapeutic efficacy of Amobarbital can be decreased when used in combination with Imipenem.
Level 2 evidence
Apalutamide
The excretion of Relebactam can be decreased when combined with Apalutamide.
Level 2 evidence
Articaine
The risk or severity of methemoglobinemia can be increased when Imipenem is combined with Articaine.
Level 1 evidence
Avibactam
The excretion of Avibactam can be decreased when combined with Cilastatin.
Level 2 evidence
Baricitinib
The excretion of Relebactam can be decreased when combined with Baricitinib.
Level 2 evidence
Baricitinib
The serum concentration of Baricitinib can be increased when it is combined with Cilastatin.
Level 1 evidence
Enter your NPI to unlock 1 major interaction for Recarbrio
Recarbrio (Imipenem Anhydrous, Cilastatin, And Relebactam Anhydrous) has 309 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Recarbrio (Imipenem Anhydrous, Cilastatin, And Relebactam Anhydrous) has 7 major, 219 moderate, and 83 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Recarbrio. Always confirm against the full prescribing information.